Merck strengthens its women’s oncology position with KEYNOTE-B96 overall survival results
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
Real-world data meets legal limits as Bayer targets ERLEADA claims in prostate cancer
Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.
Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.
What Genentech’s Lunsumio VELO approval means for relapsed follicular lymphoma treatment
FDA approves subcutaneous Lunsumio VELO for relapsed follicular lymphoma. Explore what this changes for bispecific antibodies and outpatient cancer care.